FindTrial
Sign In

The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy

The Aromatase Inhibitor and Gnrh Antagonist Versus Methotrexate for Management of Undisturbed Ectopic Pregnancy

Status
UNKNOWN
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04308343
Enrollment
120
Registered
2020-03-16
Start date
2020-03-30
Completion date
2022-09-01
Last updated
2020-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ectopic Pregnancy

Brief summary

The aim of this study is to : 1. Use of the aromatase inhibitor( letrozole) for the treatment of ectopic pregnancy compared to methotrexate. 2. Use of the Gnrh antagonist for the treatment of ectopic pregnancy compared to methotrexate.

Interventions

DRUGMethotrexate

Drugs to treat undisturbed ectopic pregnancies

DRUGLetrozole

Drugs to treat undisturbed ectopic pregnancies

DRUGcetrotide

Drugs to treat undisturbed ectopic pregnancies

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* Patients who have undisturbed ectopic pregnancy .Who are: 1. have no significant pain 2. have an unruptured tubal ectopic pregnancy with an adnexal mass smaller than 35mm with no visible heartbeat 3. have a serum human chorionic gonadotropins level less than 1,500 IU/litre 4. do not have an intrauterine pregnancy (as confirmed on an ultrasound scan) .

Exclusion criteria

1. An undisturbed ectopic pregnancy and significant pain 2. An undisturbed ectopic pregnancy with an adnexal mass of 35 mm or larger 3. An undisturbed ectopic pregnancy with a fetal heartbeat visible on an ultrasound scan 4. An undisturbed ectopic pregnancy and a serum human chorionic gonadotropins level of 5,000 IU/litre or more 5. intrauterine pregnancy

Design outcomes

Primary

MeasureTime frame
determine efficacy of the aromatase inhibitor and Gnrh antagonist to achievement of resolution of ectopic pregnancy determined by serum hCG levels below laboratory immunoassay detection <15 IU/l.Results will be statistically analyzed,then evaluated .3 months

Contacts

Primary ContactAli Saber Ali, M.Sc
kenous87@yahoo.com01095567589

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026